Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.80 |
| ▸ | NAMPT | P43490 | 5/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8917545 | 1.00 | IKBKB (0.80) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 | |
| Chs-828 SCHEMBL16312347 | 1.00 | IKBKB (0.80) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 | |
| Chs-828 SCHEMBL810990 | 1.00 | IKBKB (0.80) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8918236 | 1.00 | IKBKB (0.80) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 | |
| Chs-828 SCHEMBL7142976 | 0.99 | IKBKB (0.79) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 | |
| Chs-828 SCHEMBL7148798 | 0.99 | IKBKB (0.79) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8914914 | 0.92 | IKBKB (0.68) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14234450 | 0.90 | IKBKB (0.66) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8918690 | 0.89 | IKBKB (0.64) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8916902 | 0.89 | IKBKB (0.64) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744141-B2 | Compositions and methods for treating cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-08-18 | — | — | US | claimed |
| US-20180185382-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY | 2018-07-05 | — | — | US | claimed |
| EP-3313819-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Case Western Reserve University (US) | 2018-05-02 | — | — | EP | claimed |
| WO-2016210134-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-12-29 | — | — | WO | claimed |
| US-12083114-B2 | Inhibitors of SARM1 in combination with neuro-protective agents | DISARM THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230338363-A1 | COMBINATION CHEMO-IMMUNOTHERAPY FOR PANCREATIC CANCER USING THE IMMUNOGENIC EFFECTS OF AN IRINOTECAN SILICASOME NANOCARRIER PLUS ANTI-PD-1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338363-A1 | COMBINATION CHEMO-IMMUNOTHERAPY FOR PANCREATIC CANCER USING THE IMMUNOGENIC EFFECTS OF AN IRINOTECAN SILICASOME NANOCARRIER PLUS ANTI-PD-1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-26 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| US-20210369681-A1 | Identification of PPM1D mutations as a novel biomarker for NAMPTi sensitivity | UNIV YALE (US) | 2021-12-02 | — | — | US | disclosed |
| US-20120309797-A1 | PYRIDYL CYANOGUANIDINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-12-06 | — | — | US | disclosed |
| US-20120289604-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120270900-A1 | NOVEL METHOD OF TREATMENT | TOPO TARGET A/S (DK) | 2012-10-25 | — | — | US | disclosed |
| US-20120270900-A1 | NOVEL METHOD OF TREATMENT | TOPO TARGET A/S (DK) | 2012-10-25 | — | — | US | disclosed |
| US-8258186-B2 | Pharmaceutical for oral delivery comprising MGBG | PATHOLOGICA, LLC (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011009039-A2 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011006988-A1 | METHOD FOR PREDICTING THE UTILITY OF ADMINISTERING NICOTINIC ACID OR A PRECURSOR OR PRODRUG THEREOF TO REDUCE THE SEVERITY OF SIDE-EFFECTS OF CANCER TREATMENT WITH NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS | TOPOTARGET A/S (DK) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083114-B2 | Inhibitors of SARM1 in combination with neuro-protective agents | SARM1, SMN1; SMN2, SARNP | IKBKB 886/4885NAMPT 813/4885CYP3A4 4851/4885 |
| US-20120270900-A1 | NOVEL METHOD OF TREATMENT | NAPRT, NAMPT, NNT | IKBKB 2508/4885NAMPT 2/4885CYP3A4 1524/4885 |
| US-20180185382-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | PPP2CA, PPP3CA, PPP4C | IKBKB 702/4885NAMPT 915/4885CYP3A4 4796/4885 |
| US-10744141-B2 | Compositions and methods for treating cancer | PPP2CA, PPP3CA, PPP4C | IKBKB 702/4885NAMPT 915/4885CYP3A4 4796/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | IKBKB 3399/4885NAMPT 1/4885CYP3A4 1137/4885 |
| US-20210369681-A1 | Identification of PPM1D mutations as a novel biomarker for NAMPTi sensitivity | NAMPT, PPM1D, PPM1A | IKBKB 4239/4885NAMPT 1/4885CYP3A4 4711/4885 |
| US-20120309797-A1 | PYRIDYL CYANOGUANIDINE DERIVATIVES | PNPO, XDH, PDXK | IKBKB 2511/4885NAMPT 428/4885CYP3A4 284/4885 |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | SARM1, SMN1; SMN2, SARNP | IKBKB 886/4885NAMPT 813/4885CYP3A4 4851/4885 |
| US-20230338363-A1 | COMBINATION CHEMO-IMMUNOTHERAPY FOR PANCREATIC CANCER USING THE IMMUNOGENIC EFFECTS OF AN IRINOTECAN SILICASOME NANOCARRIER PLUS ANTI-PD-1 | SQSTM1, PDCD1, CD274 | IKBKB 419/4885NAMPT 2081/4885CYP3A4 4718/4885 |
| US-20120289604-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | IKBKB 689/4885NAMPT 569/4885CYP3A4 4873/4885 |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | IKBKB 689/4885NAMPT 569/4885CYP3A4 4873/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | IKBKB 3564/4885NAMPT 1/4885CYP3A4 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.